Key statistics dashboard for PepGen Inc. (PEPG). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Stock Data
| Price | $2.90 |
| Market Cap | $201M |
| Beta | 2.34 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -1.93 |
| Price / Book | 1.68 |
| P/S | 0.00 |
| P/FCF | -2.89 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 13.36 |
| Quick Ratio | 13.36 |
| Cash Ratio | 2.53 |
| Debt / Equity | 0.13 |
| Debt / Assets | 11.38% |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 1.73 |
| Cash per share | 1.69 |
| FCF per share | -1.00 |
| Tangible Book Value per share | 1.73 |
| Dividend per share | 0.00 |
Related companies: ALEC · APLT · CRBP · CRDF · CYBN · ELTX · FATE
Explore sector: Healthcare · Biotechnology
More sections of PEPG: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks